Free tool
FAERS Monitor: Apretude
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215499 or its brand name (Apretude, Cabotegravir). Reports on generic versions are filed under their own applications.
Reports
8,201
Serious
1,642
20% of reports
Hospitalization
363
Death reported
105
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product dose omission issue1,128
- off label use1,050
- injection site pain943
- viral load increased434
- pain414
- virologic failure270
- pyrexia259
- inappropriate schedule of product administration257
- product use in unapproved therapeutic environment254
- pathogen resistance251
- product complaint240
- drug ineffective236
- fatigue194
- injection site nodule188
- product storage error185
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 2 |
| 2017 | 16 |
| 2018 | 7 |
| 2019 | 22 |
| 2020 | 38 |
| 2021 | 253 |
| 2022 | 997 |
| 2023 | 1,934 |
| 2024 | 2,656 |
| 2025 | 1,752 |
| 2026 | 524 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,958 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product use in unapproved therapeutic environmentSignal | 254 | 1051.3 | 910.0 | 188,337 |
| viral load increasedSignal | 434 | 322.6 | 292.7 | 123,355 |
| virologic failureSignal | 270 | 135.5 | 120.1 | 34,124 |
| pathogen resistanceSignal | 251 | 72.6 | 64.2 | 17,173 |
| injection site noduleSignal | 188 | 44.6 | 38.6 | 7,830 |
| product complaintSignal | 240 | 24.5 | 21.6 | 5,345 |
| product dose omission issueSignal | 1,128 | 9.9 | 9.3 | 9,077 |
| injection site painSignal | 943 | 7.9 | 7.4 | 5,748 |
| product storage errorSignal | 185 | 5.4 | 4.7 | 665 |
| inappropriate schedule of product administrationSignal | 257 | 3.7 | 3.2 | 498 |
| off label useSignal | 1,050 | 3.1 | 2.9 | 1,533 |
| pyrexia | 259 | 1.9 | 1.7 | 115 |
| pain | 414 | 1.7 | 1.6 | 130 |
| fatigue | 194 | 0.6 | 0.6 | 41 |
| drug ineffective | 236 | 0.5 | 0.4 | 160 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.